Insider Buyers At Acelyrin Likely Disappointed With 11% Slide
Insider Buyers At Acelyrin Likely Disappointed With 11% Slide
The recent price decline of 11% in Acelyrin, Inc.'s (NASDAQ:SLRN) stock may have disappointed insiders who bought US$2.65m worth of shares at an average price of US$18.00 in the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$1.35m which is not ideal.
最近的价格下跌了11% Acelyrin, Inc. 's 纳斯达克股票代码:SLRN)的股票可能让内部人士失望,他们在过去12个月中以平均价格为18.00美元的价格购买了价值265万美元的股票。业内人士买入是期望他们的投资在一段时间内升值。但是,最近的亏损使他们的上述投资价值135万美元,这并不理想。
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
尽管我们认为股东不应简单地关注内幕交易,但我们确实认为密切关注内部人士的所作所为是完全合乎逻辑的。
View our latest analysis for Acelyrin
查看我们对 Acelyrin 的最新分析
Acelyrin Insider Transactions Over The Last Year
Acelyrin 过去一年的内幕交易
In the last twelve months, the biggest single purchase by an insider was when Independent Director Beth Seidenberg bought US$1.1m worth of shares at a price of US$18.00 per share. That means that even when the share price was higher than US$9.13 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
在过去的十二个月中,内部人士最大的单笔收购是独立董事贝丝·塞登伯格以每股18美元的价格购买了价值110万美元的股票。这意味着,即使股价高于9.13美元(最近的价格),内部人士也想购买股票。他们很有可能对这次收购感到遗憾,但他们更有可能看好该公司。在我们看来,内部人士为股票支付的价格非常重要。如果他们支付的价格高于当前价格,通常会更令人鼓舞,因为这表明即使在更高的水平上,他们也看到了价值。
In the last twelve months Acelyrin insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在过去的十二个月中,Acelyrin内部人士在买入股票,但没有卖出股票。下图显示了去年的内幕交易(公司和个人)。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231107/0-65b67e44969e4eebea1cd08faaf3ab9e-0-fde2032416201307ab7a5fead8b9ad10.png/big)
Acelyrin is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Acelyrin并不是内部人士唯一买入的股票。对于那些喜欢寻找的人 获胜的投资 这个 免费的 最近进行内幕收购的成长型公司名单可能只是门票。
Insider Ownership Of Acelyrin
Acelyrin 的内部所有权
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 2.5% of Acelyrin shares, worth about US$22m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
检验公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股票。较高的内部人所有权通常会使公司领导层更加关注股东的利益。业内人士拥有Acelyrin2.5%的股份,价值约2200万美元。这种内部所有权水平不错,但还差一点特别突出。当然,这确实表明了一定程度的一致性。
So What Does This Data Suggest About Acelyrin Insiders?
那么,这些数据对Acelyrin Insiders有何启示呢?
There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. Overall we don't see anything to make us think Acelyrin insiders are doubting the company, and they do own shares. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Acelyrin. To help with this, we've discovered 4 warning signs (3 are a bit unpleasant!) that you ought to be aware of before buying any shares in Acelyrin.
在过去的三个月中,没有任何内幕交易——这并不意味着什么。令人鼓舞的是,去年的交易令人鼓舞。总的来说,我们认为没有任何东西可以让我们认为Acelyrin内部人士正在怀疑该公司,他们确实拥有股票。除了了解正在进行的内幕交易外,确定Acelyrin面临的风险也是有益的。为了帮助解决这个问题,我们发现了 4 个警告标志 (3 有点不愉快!)在购买Acelyrin的任何股票之前,你应该意识到这一点。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想去另一家公司看看 —— 一家财务状况可能优异的公司 —— 那千万不要错过这个 免费的 股本回报率高、债务低的有趣公司名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。